Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E E4 Carriers. [For extension study, see profile 700227453]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- 19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 27 Jul 2020 This trial is completed in UK (Global End Date: 06 Aug 2012), according to European Clinical Trials Database record.